The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma

The prevention of recurrence after colorectal adenoma resection remains an urgent medical issue to be addressed. Previous studies have mainly focused on nonsteroidal anti-inflammatory drugs, calcium supplements, and vitamins. The gut microbiota and its metabolic products are believed to play a potential role in the development and progression of colorectal adenomas. Clostridium butyricum, a butyrate-producing probiotic, has not yet been studied for its potential in preventing the recurrence of colorectal adenomas following resection. Therefore, this study, designed as a multicenter, double-blind, placebo-controlled randomized controlled trial, aims to explore evidence-based data on the role of Clostridium butyricum in preventing colorectal adenoma recurrence.

NCT Number	NCT07167342
Lead Sponsor	The Affiliated Hospital of Qingdao University Collaborators: Shandong Cancer Hospital and Institute, Yantai Yuhuangding Hospital, Rizhao People's Hospital, Qianfoshan Hospital, Weifang People's Hospital, Dongying People's Hospital, Peking University People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Bengbu Medical University
Conditions	Colorectal Adenoma, Probiotics
Enrollment	294 participants
Start Date	2026-05-22
Primary Completion	2030-04-30 (estimated)
Study Completion	2030-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-26